KSQ-logo-color_RegTM copy.png
KSQ Therapeutics Appoints John Lepore, M.D., to its Board of Directors
22 oct. 2024 07h00 HE | KSQ
KSQ Therapeutics Appoints John Lepore, M.D., to its Board of Directors
KSQ-logo-color_RegTM copy.png
KSQ Therapeutics Appoints Anna Truppel-Hartmann, M.D., as Chief Medical Officer
08 oct. 2024 07h00 HE | KSQ
KSQ Therapeutics Appoints Anna Truppel-Hartmann, M.D., as Chief Medical Officer
KSQ-logo-color_RegTM copy.png
KSQ Therapeutics Announces FDA Clearance of IND Application for KSQ-004EX, a CRISPR/Cas9 Engineered Tumor-Infiltrating Lymphocyte (eTIL®) Therapy
24 sept. 2024 07h00 HE | KSQ
KSQ Therapeutics Announces FDA Clearance of IND Application for KSQ-004EX, a CRISPR/Cas9 Engineered Tumor-Infiltrating Lymphocyte (eTIL®) Therapy
KSQ-logo-color_RegTM copy.png
KSQ Therapeutics to Participate in Upcoming Investor Conferences
28 août 2024 07h00 HE | KSQ
KSQ Therapeutics to Participate in Upcoming Investor Conferences
KSQ-logo-color_RegTM copy.png
KSQ Therapeutics Announces First Patient Dosed in Clinical Development Program for KSQ-001EX, a CRISPR/Cas9 Engineered Tumor Infiltrating Lymphocyte (eTIL®) Therapy
12 juin 2024 07h00 HE | KSQ
KSQ Therapeutics Announces First Patient Dosed in Clinical Development Program for KSQ-001EX, a CRISPR/Cas9 Engineered eTIL® Therapy
KSQ-logo-color_RegTM copy.png
KSQ Therapeutics Announces FDA Clearance of IND Application for KSQ-001EX, a CRISPR/Cas9 Engineered Tumor Infiltrating Lymphocyte (eTIL®) Therapy
29 nov. 2023 07h00 HE | KSQ
KSQ Therapeutics Announces FDA Clearance of IND Application for KSQ-001EX, a CRISPR/Cas9 Engineered Tumor Infiltrating Lymphocyte (eTIL®) Therapy